Baili-Ballentine's Izalontamab Brengitecan Phase 3 PANKU-Breast01 Results Published in The Lancet, cORR 40.5%, mPFS 8.2 Months

Baili-Ballentine's bispecific ADC izalontamab brengitecan showed a cORR of 40.5% and mPFS of 8.2 months in the phase 3 PANKU-Breast01 study in HR+/HER2- advanced breast cancer. The comparator cORR was 20.2%, mPFS was extended by 4.2 months, and the risk of progression or death was reduced by 59% (HR=0.41); ILD occurred in 1.1% of patients, all grade 1-2. The marketing application for this new indication has been accepted, and the results were published in The Lancet and presented at the ESMO congress.